Friday, 01 December 2017 04:12

We can all make a difference...

Written by
Once upon a time, there was an old man who used to go to the ocean to do his writing. He had a habit of walking on the beach every morning before he began his work. Early one morning, he was walking…
The combination of Sovaldi (Sofosbuvir) and Daklinza (Daclatasvir) was the world's first pan-genotypic Hepatitis C treatment. In the USA and Europe the $140,000 price tag of this combination means it has seen relatively little use, but in the world of generics it…
Monday, 20 November 2017 21:27

What happens when you finish your Hep C treatment?

Written by
Recently I have been getting a number of enquires from patients who have just finished their tablets, all asking the same questions, so here is a quick primer. If you are looking for this sort of information you will find a lot…
Thursday, 16 November 2017 20:50

71% decrease in cancer rate for Hep C patients with SVR

Written by
Some time ago we saw some very bad science published. This suggested that treating Hepatitis C confers no benefits. While experts around the world expressed their firm view this was complete and utter rubbish here is something simple to understand. Get treated,…
KUALA LUMPUR/GENEVA – 13th November 2017 – Malaysian pharmaceutical company Pharmaniaga Logistics Sdn Bhd (Pharmaniaga), Egyptian pharmaceutical company Pharco Pharmaceuticals (Pharco) and non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration agreement to supply a new…
We have the power to FixHepC, but the real question is... Do we have the willpower? This was how Dr James Freeman ended his presentation at the World Hepatitis Summit in Brazil. You can watch the full presentation on YouTube. In essence,…
Hepatitis C is a disease that can make you feel old before your time. While there is no doubt that treatment with the new generation of direct acting antivirals like Harvoni is by far the best option this is not available to…
About 1 in 100 people, from all walks of life, have Hepatitis C so it is pretty common. Because it is a highly stigmatised disease, linked in the public mind to IV drug use, most patients choose to keep their diagnosis confidential.…
Just out of embargo for AASLD 2017 is the rather innocuous sounding Abstract 1078 which says, in brief, that these generic DAAs are inarguably proven the same as the originator DAAs.Bioequivalent pharmacokinetics for generic and originator Hepatitis C Direct Acting Antivirals Andrew M.…
Switzerland has just announced that all limitations on access to the new DAAs will be abolished allowing treatment for all. Great news for Swiss patients. Here is an article from the Swiss Hepatitis C Association about it. If you are not lucky…
Wednesday, 20 September 2017 01:52

The Effects of Hepatitis C on Your Body

Written by
What exactly is chronic HCV? In a nutshell, it refers to ongoing inflammation of your liver. But it can lead to symptoms throughout your body. Over time, living with this condition can cause your body to be especially vulnerable to serious health…
Tuesday, 29 August 2017 04:12

Access Versus Praccess

Written by
Last week there was some celebrations after Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries. So great news, right? Not exactly, because in order for a country to have PRACTICAL ACCESS the product needs to be registered for sale…
By Priti Krishtel Last week, the FDA approved AbbVie’s Mavyret—a new hepatitis C virus (HCV) drug that treats all genotypes of the disease and cures more than 90% of patients within just 8 weeks of treatment. This has been reported as a…
"To our knowledge, this is the first large-scale study to demonstrate the effect of newer DAA regimens upon survival. Treatment with 2 commonly used DAA regimens, PrOD and LDV/SOF, was associated with significant improvements in survival within the first 18 months of…
Sunday, 23 July 2017 11:21

Crisis, What Crisis? - Practivism

Written by
Here is a copy of the presentation, called "Practivism, it's the new black", given by Dr James Freeman at the International AIDS society meeting in Paris today. Here is the text that went with the images. Crisis, What Crisis? This crisis. Look at this…
Saturday, 15 July 2017 01:49

Direct Acting Antivirals and Liver Cancer Risk

Written by
Over the past year there has been quite a lot of discussion about the risk of liver cancer following treatment with Direct Acting Antivirals like Harvoni® and Sovaldi®. Here is a quick explanation and the latest thinking from the academic gurus. First,…
Here is the response from EASL to the recent Cochrane review. http://www.journal-of-hepatology.eu/pb/assets/raw/Health%20Advance/journals/jhepat/CochraneEASLJMP003.pdf EASL, the European Association for the Study of the Liver, one of the world leading associations of liver specialists, feels compelled to express its serious concerns after the recent publication…
This article was just published in the Lancet The introduction of direct-acting antiviral (DAA) medicines in 2013 revolutionised the treatment of chronic hepatitis C virus (HCV) infection. The efficacy of DAA therapy is impressive—in many clinical trials HCV cannot be detected by…
Saturday, 01 July 2017 00:55

How do I fix my insomnia

Written by
About 1 in 5 patients taking Direct Acting Antivirals will get insomnia. Here is a post of mine from some years ago about how to manage it. Insomnia is a common and often frustrating problem. Part of the reason it's frustrating is…
Friday, 09 June 2017 01:34

Bad Science

Written by
Yesterday the Guardian published an article called 'Miracle' hepatitis C drugs costing £30k per patient 'may have no clinical effect' https://www.theguardian.com/society/2017/jun/08/miracle-hepatitis-c-drugs-costing-30k-per-patient-may-have-no-clinical-effect The problem with this sensationalist headline is that while it is reporting what was said by the Cochrane Collaboration what they looked at…
Tuesday, 02 May 2017 04:50

Reversal Of Liver Fibrosis - Then and Now

Written by
There is some really interesting stuff happening in the "reverse liver fibrosis" realm. Here is state of the art in 2009 (great review of the mechanism) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702953/ where we had no clear candidates, and Here is state of the art in 2015…
Friday, 21 April 2017 22:17

EASL 2017 Generics Results

Written by
Here is a copy of the generic hep c medication presentation given by Dr James Freeman at EASL 2017 today. Mostly the presentation followed the slides. The last words, with the last slide were "I want everyone to join the club, not…
Friday, 14 April 2017 08:33

A Brief History Of Sofosbuvir

Written by
“The Liver Meeting”, or AASLD 2011, was taking place at the great, glass-fronted Moscone West Convention Center in downtown San Francisco. Almost 9,000 people were there – family doctors, hepatologists, gastroenterologists, academics, drug salesmen, public health officials – all networking, trudging the…
Friday, 31 March 2017 04:32

The Story Of Generics Hits The Lancet

Written by
An article with the title: Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries just made it into the Lancet print edition: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32051-7/fulltext There is a PDF of it here

Copyright © 2015-2019 FixHepC

Back to Top